ADC Therapeutics (ADCT) Stock Statistics & Valuation Metrics

ADC Therapeutics has a market cap or net worth of $266.79M. The enterprise value is $465.30M.

ADC Therapeutics has 99,178,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

ADC Therapeutics’s return on equity (ROE) is 0.78 and return on invested capital (ROIC) is -53.85%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, ADC Therapeutics had revenue of 69.28M and earned -157.85M in profits. Earnings per share was -1.62.

In the last 12 months, operating cash flow was -30.75M and capital expenditures -247.00K, giving a free cash flow of -30.99M billion.

ADC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

ADC Therapeutics upcoming earnings date is Aug 12, 2025, Before Open (Confirmed).

ADC Therapeutics as a current ratio of 3.82, with Debt / Equity ratio of -140.50%

In the past 12 months, ADC Therapeutics has paid 166.00K in taxes.

ADC Therapeutics EV to EBITDA ratio is -0.63, with an EV/FCF ratio of -0.53.

ADC Therapeutics has $194.70M in cash and marketable securities with $334.70M in debt, giving a net cash position of $140.00M billion.

Gross margin is 90.97%, with operating margin of -188.59%, and net profit margin of -227.84%.

The average price target for ADC Therapeutics is $7.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy